Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up
- Resource Type
- Article
- Source
- In
Journal of Thoracic Oncology August 2024 19(8):1228-1241 - Subject
- Language
- ISSN
- 1556-0864